DHODH and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast with AML, differentiation therapy in CML is not the main goal of treatment, and developing a more potent DHODH inhibitor that can eliminate leukemic cells while preserving its selectivity is of paramount importance.